{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:27:58Z","timestamp":1786883278988,"version":"build-2736575974"},"reference-count":107,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacl.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:44:15Z","timestamp":1776728655000},"page":"1312-1324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unmet needs for lipid management in patients with peripheral arterial disease: A narrative review"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-8631","authenticated-orcid":false,"given":"Demetria M.","family":"Bolden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9230-4276","authenticated-orcid":false,"given":"Mary Katherine","family":"Cheeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry Craig","family":"Tedder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jacl.2026.04.016_bib1","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.016_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jvs.2014.03.290","article-title":"Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population","volume":"60","author":"Nehler","year":"2014","journal-title":"J Vasc Surg"},{"issue":"19","key":"10.1016\/j.jacl.2026.04.016_bib3","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.04.016_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2019.09.012","article-title":"Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review","volume":"293","author":"Agnelli","year":"2020","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jacl.2026.04.016_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.300.2.197","article-title":"Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis","volume":"300","author":"Fowkes","year":"2008","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jacl.2026.04.016_bib6","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacl.2026.04.016_bib7","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and polyvascular disease","volume":"128","author":"Aday","year":"2021","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.jacl.2026.04.016_bib8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCRESAHA.114.303517","article-title":"Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia","volume":"116","author":"McDermott","year":"2015","journal-title":"Circ Res"},{"issue":"24","key":"10.1016\/j.jacl.2026.04.016_bib9","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.jacl.2026.04.016_bib10","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC Guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacl.2026.04.016_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000257","article-title":"Ankle brachial index values, leg symptoms, and functional performance among community-dwelling older men and women in the lifestyle interventions and independence for elders study","volume":"2","author":"McDermott","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004519","article-title":"Lower extremity peripheral artery disease and quality of life among older individuals in the community","volume":"6","author":"Wu","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.jacl.2026.04.016_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207456","article-title":"Living a burdensome and demanding life: a qualitative systematic review of the patients experiences of peripheral arterial disease","volume":"13","author":"Abaraogu","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jacl.2026.04.016_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jvs.2017.06.102","article-title":"Estimated annual health care expenditures in individuals with peripheral arterial disease","volume":"67","author":"Scully","year":"2018","journal-title":"J Vasc Surg"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.016_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejvs.2015.10.022","article-title":"The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease","volume":"51","author":"Sigvant","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jacl.2026.04.016_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/VHRM.S209241","article-title":"The burden of critical limb ischemia: a review of recent literature","volume":"15","author":"Duff","year":"2019","journal-title":"Vasc Health Risk Manag"},{"issue":"20","key":"10.1016\/j.jacl.2026.04.016_bib17","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial","volume":"71","author":"Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacl.2026.04.016_bib18","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1001\/archinte.165.16.1896","article-title":"Risk factors for declining ankle-brachial index in men and women 65 years or older: the Cardiovascular Health Study","volume":"165","author":"Kennedy","year":"2005","journal-title":"Arch Intern Med"},{"issue":"19","key":"10.1016\/j.jacl.2026.04.016_bib19","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/jama.285.19.2481","article-title":"Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease","volume":"285","author":"Ridker","year":"2001","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.jacl.2026.04.016_bib20","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","article-title":"Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence","volume":"138","author":"Aday","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.016_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1161\/ATVBAHA.120.315828","article-title":"Conventional and novel lipid measures and risk of peripheral artery disease","volume":"41","author":"Kou","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.04.016_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.696695","article-title":"Association between cumulative exposure to increased low-density lipoprotein cholesterol and the new occurrence of peripheral artery disease","volume":"12","author":"Liu","year":"2021","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.016_bib23","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2026.04.016_bib24","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.04.016_bib25","unstructured":"American Heart Association. PAD National Action Plan. Accessed January 8, 2024. https:\/\/professional.heart.org\/en\/science-news\/pad-national-action-plan."},{"issue":"17","key":"10.1016\/j.jacl.2026.04.016_bib26","doi-asserted-by":"crossref","first-page":"e875","DOI":"10.1161\/CIR.0000000000000967","article-title":"Reducing nontraumatic lower-extremity amputations by 20% by 2030: time to get to our feet: a policy statement from the American Heart Association","volume":"143","author":"Creager","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.016_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejvs.2024.01.009","volume":"67","author":"Mazzolai","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"12","key":"10.1016\/j.jacl.2026.04.016_bib28","article-title":"Exercise for intermittent claudication","volume":"12","author":"Lane","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jacl.2026.04.016_bib29","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jvs.2012.04.046","article-title":"Supervised walking therapy in patients with intermittent claudication","volume":"56","author":"Fakhry","year":"2012","journal-title":"J Vasc Surg"},{"issue":"12","key":"10.1016\/j.jacl.2026.04.016_bib30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jacc.2023.01.025","article-title":"Integrating psychosocial care in the management of patients with vascular disease","volume":"81","author":"Smolderen","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jacl.2026.04.016_bib31","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.jacc.2019.03.463","article-title":"Vascular teams in peripheral vascular disease","volume":"73","author":"Kolte","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6s","key":"10.1016\/j.jacl.2026.04.016_bib32","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jacl.2026.04.016_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.11.027","article-title":"Management of peripheral artery disease in adults with diabetes: 2025 ACC Scientific Statement: a report of the American College of Cardiology","author":"Das","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2026.04.016_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","author":"Heart Protection Study Collaborative Group","year":"2007","journal-title":"J Vasc Surg"},{"issue":"14","key":"10.1016\/j.jacl.2026.04.016_bib35","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","article-title":"Association of statin dose with amputation and survival in patients with peripheral artery disease","volume":"137","author":"Arya","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2026.04.016_bib36","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1055\/s-0040-1709711","article-title":"Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis","volume":"120","author":"Pastori","year":"2020","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.jacl.2026.04.016_bib37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"10.1016\/j.jacl.2026.04.016_bib38","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacl.2026.04.016_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2026.04.016_bib40","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.04.016_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.carrev.2023.04.020","article-title":"The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study)","volume":"55","author":"Clavijo","year":"2023","journal-title":"Cardiovasc Revasc Med"},{"issue":"18","key":"10.1016\/j.jacl.2026.04.016_bib42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"47","key":"10.1016\/j.jacl.2026.04.016_bib43","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1093\/eurheartj\/ehab604","article-title":"Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial","volume":"42","author":"Oyama","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacl.2026.04.016_bib44","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacl.2026.04.016_bib45","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jacl.2026.04.016_bib46","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.jacl.2026.04.016_bib47","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.04.016_bib48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.04.016_bib49","unstructured":"Novartis Pharmaceuticals. ORION-4: a double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease. Accessed May 21, 2026. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03705234."},{"key":"10.1016\/j.jacl.2026.04.016_bib50","unstructured":"Novartis Pharmaceuticals. A\u00a0randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT). Accessed May 21, 2026. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05030428."},{"issue":"24","key":"10.1016\/j.jacl.2026.04.016_bib51","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2026.04.016_bib52","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/MOL.0000000000000999","article-title":"Peripheral arterial disease associated with elevated lipoprotein(a): a review of the evidence and treatment approaches","volume":"36","author":"Bhatia","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2026.04.016_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"24","key":"10.1016\/j.jacl.2026.04.016_bib54","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.jacc.2023.10.015","article-title":"Lipoprotein(a), peripheral artery disease, and abdominal aortic aneurysm: the next frontier or another risk enhancer?","volume":"82","author":"Beckman","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib55","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/intqhc\/mzv115","article-title":"Guide to clinical practice guidelines: the current state of play","volume":"28","author":"Kredo","year":"2016","journal-title":"Int J Qual Health Care"},{"issue":"10090","key":"10.1016\/j.jacl.2026.04.016_bib56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(16)30946-1","article-title":"Evidence for underuse of effective medical services around the world","volume":"390","author":"Glasziou","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1358863X20957091","article-title":"Lipid-lowering therapies in peripheral artery disease: a review","volume":"26","author":"Skeik","year":"2021","journal-title":"Vasc Med"},{"issue":"6","key":"10.1016\/j.jacl.2026.04.016_bib58","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jacc.2005.10.009","article-title":"ACC\/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary","volume":"47","author":"Hirsch","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2026.04.016_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25505","article-title":"Assessment of trends in statin therapy for secondary prevention of atherosclerotic cardiovascular disease in US adults from 2007 to 2016","volume":"3","author":"Yao","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1358863X19871100","article-title":"Trends in statin utilization among adults with severe peripheral artery disease including critical limb ischemia in an integrated healthcare delivery system","volume":"25","author":"Reynolds","year":"2020","journal-title":"Vasc Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.04.016_bib61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/1358863X221145533","article-title":"Medical therapies, comorbid conditions, and functional performance in people with peripheral artery disease enrolled in clinical trials between 2004 and 2021","volume":"28","author":"Nayak","year":"2023","journal-title":"Vasc Med"},{"issue":"25","key":"10.1016\/j.jacl.2026.04.016_bib62","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.jacc.2024.04.034","article-title":"Randomized trial of a vascular care team vs education for patients with peripheral artery disease","volume":"83","author":"Hess","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.04.016_bib63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.semvascsurg.2022.05.003","article-title":"Disparities in peripheral artery disease care: a review and call for action","volume":"35","author":"Demsas","year":"2022","journal-title":"Semin Vasc Surg"},{"issue":"2","key":"10.1016\/j.jacl.2026.04.016_bib64","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007425","article-title":"Race and socioeconomic status independently affect risk of major amputation in peripheral artery disease","volume":"7","author":"Arya","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.016_bib65","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIR.0000000000001153","article-title":"Health disparities in peripheral artery disease: a scientific statement from the American Heart Association","volume":"148","author":"Allison","year":"2023","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jacl.2026.04.016_bib66","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2023.09.830","article-title":"Disparities in diagnosis, treatment, and outcomes of peripheral artery disease","volume":"82","author":"McDermott","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2026.04.016_bib67","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.jvs.2022.01.120","article-title":"Contemporary outcomes of limb-salvage procedures using Vascular Quality Initiative-Medicare-linked data: racial and ethnic disparities persist","volume":"75","author":"Mathlouthi","year":"2022","journal-title":"J Vasc Surg"},{"issue":"18","key":"10.1016\/j.jacl.2026.04.016_bib68","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2021.17764","article-title":"A policy prescription for reducing health disparities-achieving pharmacoequity","volume":"326","author":"Essien","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jacl.2026.04.016_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008109","article-title":"Implementation science opportunities in cardiovascular medicine","volume":"14","author":"Galaviz","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"10.1016\/j.jacl.2026.04.016_bib70","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3122\/jabfm.2022.210449R1","article-title":"Tailoring implementation strategies for cardiovascular disease risk calculator adoption in primary care clinics","volume":"35","author":"Baldwin","year":"2022","journal-title":"J Am Board Fam Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12961-020-00588-8","article-title":"Individual, health system, and contextual barriers and facilitators for the implementation of clinical practice guidelines: a systematic metareview","volume":"18","author":"Correa","year":"2020","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.jacl.2026.04.016_bib72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1748-5908-8-35","article-title":"A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice","volume":"8","author":"Flottorp","year":"2013","journal-title":"Implement Sci"},{"key":"10.1016\/j.jacl.2026.04.016_bib73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6947-8-38","article-title":"Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review","volume":"8","author":"Francke","year":"2008","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062158","article-title":"Barriers and enablers to implementing clinical practice guidelines in primary care: an overview of systematic reviews","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"issue":"9391","key":"10.1016\/j.jacl.2026.04.016_bib75","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(03)14546-1","article-title":"From best evidence to best practice: effective implementation of change in patients' care","volume":"362","author":"Grol","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11886-024-02174-8","article-title":"Learnings from implementation strategies to improve lipid management","volume":"27","author":"Lan","year":"2025","journal-title":"Curr Cardiol Rep"},{"issue":"suppl_4","key":"10.1016\/j.jacl.2026.04.016_bib77","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/ajhp\/zxae097","article-title":"Pharmacist optimization of lipid therapy in patients with peripheral vascular disease","volume":"81","author":"Tucker","year":"2024","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.jacl.2026.04.016_bib78","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1024\/0301-1526\/a000945","article-title":"International public awareness of peripheral artery disease","volume":"50","author":"Bauersachs","year":"2021","journal-title":"Vasa"},{"issue":"7","key":"10.1016\/j.jacl.2026.04.016_bib79","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.016_bib80","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"8","key":"10.1016\/j.jacl.2026.04.016_bib81","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamacardio.2019.1972","article-title":"Fear-based medical misinformation and disease prevention: from vaccines to statins","volume":"4","author":"Navar","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2026.04.016_bib82","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.04.016_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100281","article-title":"Shared decision making and patient reported outcomes among adults with atherosclerotic cardiovascular disease, medical expenditure panel survey 2006-2015","volume":"8","author":"Okunrintemi","year":"2021","journal-title":"Am J Prev Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2026.04.016_bib84","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.mayocp.2021.02.032","article-title":"High-intensity statins benefit high-risk patients: why and how to do better","volume":"96","author":"Grundy","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2026.04.016_bib85","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.atherosclerosis.2021.03.013","article-title":"Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: a pragmatic randomized controlled trial","volume":"323","author":"Zafeiropoulos","year":"2021","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.jacl.2026.04.016_bib86","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1007\/s12325-024-02916-8","article-title":"Differential adherence to free and single-pill combination of rosuvastatin\/ezetimibe: findings from a real-world analysis in Italy","volume":"41","author":"Perez de Isla","year":"2024","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.jacl.2026.04.016_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14041383","article-title":"Diabetes in peripheral artery disease: prevalence, complications, and polypharmacy","volume":"14","author":"Baty","year":"2025","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.jacl.2026.04.016_bib88","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.124.011804","article-title":"Quantifying patient preferences about features of nonstatin lipid-lowering therapies: a discrete choice experiment in the United States","volume":"18","author":"Reed","year":"2025","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"10.1016\/j.jacl.2026.04.016_bib89","first-page":"737","article-title":"Multidisciplinary teams in clinical lipidology and cardiometabolic care: a National Lipid Association Expert Clinical Review","volume":"19","author":"Cheeley","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib90","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s43058-021-00135-8","article-title":"Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis","volume":"2","author":"Jones","year":"2021","journal-title":"Implement Sci Commun"},{"key":"10.1016\/j.jacl.2026.04.016_bib91","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.atherosclerosissup.2021.01.010","article-title":"Implementation of clinical practices and pathways optimizing ACS patients lipid management: focus on eight European initiatives","volume":"42","author":"Alings","year":"2020","journal-title":"Atheroscler Suppl"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.016_bib92","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1358863X19893003","article-title":"Knowledge of peripheral artery disease: what do the public, healthcare practitioners, and trainees know?","volume":"25","author":"Bridgwood","year":"2020","journal-title":"Vasc Med"},{"issue":"22","key":"10.1016\/j.jacl.2026.04.016_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11226619","article-title":"False versus true statin intolerance in patients with peripheral artery disease","volume":"11","author":"Dopheide","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.jacl.2026.04.016_bib94","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacl.2022.07.009","article-title":"Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome","volume":"16","author":"Garc\u00eda","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.04.016_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100472","article-title":"The importance of low-density lipoprotein cholesterol measurement and control as performance measures: a joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology","volume":"13","author":"Virani","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.04.016_bib96","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","article-title":"RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review","volume":"7","author":"Glasgow","year":"2019","journal-title":"Front Public Health"},{"issue":"9","key":"10.1016\/j.jacl.2026.04.016_bib97","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","article-title":"Evaluating the public health impact of health promotion interventions: the RE-AIM framework","volume":"89","author":"Glasgow","year":"1999","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.016_bib98","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyaf039","article-title":"Practical application of hybrid effectiveness\u2013implementation studies for intervention research","volume":"54","author":"Handley","year":"2025","journal-title":"Int J Epidemiol"},{"issue":"19","key":"10.1016\/j.jacl.2026.04.016_bib99","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1161\/CIR.0000000000001096","article-title":"Leveraging implementation science for cardiovascular health equity: a scientific statement from the American Heart Association","volume":"146","author":"Moise","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib100","first-page":"21","article-title":"A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project","volume":"10","author":"Powell","year":"2015","journal-title":"Implement\u00a0Sci"},{"key":"10.1016\/j.jacl.2026.04.016_bib101","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13012-015-0295-0","article-title":"Use of concept mapping to characterize relationships among implementation strategies and assess their feasibility and importance: results from the Expert Recommendations for Implementing Change (ERIC) study","volume":"10","author":"Waltz","year":"2015","journal-title":"Implement Sci"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.016_bib102","first-page":"13","article-title":"Addressing health disparities through implementation science\u2014a need to integrate an equity lens from the outset","volume":"17","author":"Kerkhoff","year":"2022","journal-title":"Implement\u00a0Sci"},{"key":"10.1016\/j.jacl.2026.04.016_bib103","unstructured":"Barnes G.D. Health disparities in peripheral artery disease: key points. Accessed October 30, 2024. https:\/\/www.acc.org\/latest-in-cardiology\/ten-points-to-remember\/2023\/07\/28\/14\/44\/health-disparities-in-pad."},{"issue":"5","key":"10.1016\/j.jacl.2026.04.016_bib104","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/jcm13051251","article-title":"Novel and emerging LDL-C lowering strategies: a new era of dyslipidemia management","volume":"13","author":"Agnello","year":"2024","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.jacl.2026.04.016_bib105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028892","article-title":"Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum","volume":"12","author":"Wilkinson","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.04.016_bib106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1748-5908-7-109","article-title":"Strategies for monitoring and updating clinical practice guidelines: a systematic review","volume":"7","author":"Mart\u00ednez Garc\u00eda","year":"2012","journal-title":"Implement Sci"},{"issue":"24","key":"10.1016\/j.jacl.2026.04.016_bib107","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1161\/CIRCULATIONAHA.123.066177","article-title":"Overcoming challenges to implementing new evidence for low-dose anticoagulant use in peripheral artery disease","volume":"148","author":"Chaitoff","year":"2023","journal-title":"Circulation"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:30:44Z","timestamp":1786879844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":107,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1933287426001194"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.04.016","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs for lipid management in patients with peripheral arterial disease: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}